Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Scientific Reports|October 12, 2019
Raman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer LumpectomyWillie C Zúñiga, Veronica Jones, Sarah M Anderson, et al.
Cancers|June 10, 2022
Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast CancerAdam L Maddox, Matthew S Brehove, Kiarash R Eliato, et al.
Oncoimmunology|December 7, 2017
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumabYuan Yuan, Ferdynand J Kos, Ting-Fang He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2019
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsKatherine E Hutchinson, Susan E Yost, Ching-Wei Chang, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 23, 2025
YAP1 dysfunction promotes molecular properties linked to breast cancer susceptibilityTara Fresques, Jennifer C Lopez, Deborah Hussey, et al.
Plos One|March 10, 2020
Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosisTing-Fang He, Susan E Yost, Paul H Frankel, et al.
JCI Insight|July 10, 2023
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphomaZhen Han, Xiwei Wu, Hanjun Qin, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancerKavitha Mukund, Darya Veraksa, David Frankhouser, et al.
Cancers|July 9, 2022
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast CancerJin Sun Lee, Susan E Yost, Sierra Min Li, et al.
The Oncologist|April 6, 2023
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast CancerYuan Yuan, Susan E Yost, Yujie Cui, et al.
Pageof 6